RegulinkedSaudi Food and Drug Authority (SFDA) has issued Version 1.0 of new guidelines defining chemical and pharmaceutical quality documentation requirements for small-molecule investigational products (IPs) in clinical trials.
Summary:
The guideline introduces structured dossier expectations to support Clinical Trial Application for Investigational Product Dossiers (IPDs) submitted to SFDA prior to initiating clinical trials in humans. Adapted from the European Medicines Agency framework, it applies to chemically defined substances, synthetic peptides, herbal preparations, and radiolabeled products.
🔍 What’s New
• Introduces a mandatory structured IPD format (Chapters 2–8).
• Requires submission of the most up-to-date quality data at the time of CTA filing.
• Confirms applicability to investigational, comparator, modified authorised, placebo, and bioequivalence products.
• Reinforces GMP compliance for investigational product manufacturing.
• Clarifies regional administrative requirements, including alcohol- and pork-content declaration letters.
• Defines expectations for stability data, impurity control, and amendment documentation throughout clinical development.
💡 Why it Matters
Sponsors must ensure compliant quality documentation, manufacturing controls, and timely data readiness to support efficient SFDA clinical trial approvals and appropriate safety evaluation.
📌 How ReguLinked Can Support
Dossier / eCTD: Structuring IPDs in line with SFDA quality and numbering requirements.
Clinical Regulatory Strategy: Aligning CTA submissions with stability and CMC expectations.
Market Access Readiness: Preparing clinical assets for future registration pathways in Saudi Arabia.
Planning to assess the impact of this SFDA guideline on your clinical development plans?
Let ReguLinked support your regulatory readiness with a fully compliant with SFDA strategy.
Book your complimentary consultation today
📧 bd@regulinked.com
| 🌐 www.regulinked.com
📎 Official Source: Small molecules Ivestigational Products
#ReguLinked #SFDA #SaudiArabia #ClinicalTrials #InvestigationalProducts #GMPCompliance #RegulatoryAffairs #MarketAccess
